Aniridia Clinical Trial
Official title:
RAFT - First in Human Phase I/II Clinical Trial of RAFT for Aniridia Related Keratopathy
The RAFT trial is a first in human trial of a novel cellular therapy called RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) developed and manufactured by Cells for Sight Stem Cell Therapy Research Unit at UCL institute of Ophthalmology. The aim of this seamless phase I/II single-dose, single-arm trial is to investigate if RAFT-OS is a safe and effective alternative treatment for patients with aniridia related keratopathy (ARK) in 21 patients. ARK is a complication of aniridia, which is a genetic eye condition present from birth. RAFT-OS is an artificial tissue, populated with limbal epithelial cells and stromal cells. The source of the adult limbal and stromal cells is from donated human corneas from the NHS blood and Transplant, Tissue and Eye services in Liverpool. Following a Screening visit, participants will commence 10-weeks of immune suppression therapy to prepare for the transplantation of RAFT-OS. The RAFT-OS will be transplanted into the participants worst affected eye. Following surgery, each participant will be assessed at days 1, 7, 14, 21, and 1-month for major or intermediate safety events. Participants will continue to be followed up to 12 months after transplantation and will be required to stay on the immune suppression therapy for the duration of the trial. The trial is conducted at Moorfields Eye Hospital NHS Foundation Trust (MEH), London in the United Kingdom (UK). MEH is a leading provider of eye health services in the UK and is a world-class centre of excellence for ophthalmic research and education. All trial medical assessments and procedures will be performed in an appropriate clinical setting by suitability qualified staff.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00758108 -
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
|
||
| Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
| Recruiting |
NCT05400590 -
Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
|
||
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT00001161 -
Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens
|
N/A | |
| Enrolling by invitation |
NCT03461978 -
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
|
N/A | |
| Recruiting |
NCT05954403 -
National Cohort on Congenital Defects of the Eye
|
||
| Completed |
NCT02647359 -
Study of Ataluren in Participants With Nonsense Mutation Aniridia
|
Phase 2 | |
| Completed |
NCT03581864 -
Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
|
||
| Recruiting |
NCT05562115 -
Proteomic Study of Tears From Patients With a PAX6 Mutation
|
N/A | |
| Completed |
NCT00265590 -
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
|
N/A | |
| Withdrawn |
NCT04117880 -
A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
|
Phase 2 | |
| Active, not recruiting |
NCT00503893 -
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
|
||
| Completed |
NCT01644552 -
Positive Angle Kappa
|
||
| Completed |
NCT00812708 -
Clinical Evaluation of Morcher Artificial Iris Diaphragms
|
N/A |